New therapeutic targets in the management of urothelial carcinoma of the bladder

Einar F Sverrisson, Patrick N Espiritu, Philippe E SpiessDepartment of Genitourinary Oncology, H Lee Moffitt Cancer Center, Tampa, FL, USAAbstract: Urothelial carcinoma of the bladder, despite the myriad of treatment approaches and our progressively increasing knowledge into its disease processes, r...

Full description

Bibliographic Details
Main Authors: Sverrisson EF, Espiritu PN, Spiess PE
Format: Article
Language:English
Published: Dove Medical Press 2013-03-01
Series:Research and Reports in Urology
Online Access:http://www.dovepress.com/new-therapeutic-targets-in-the-management-of-urothelial-carcinoma-of-t-a12337
id doaj-1213022982c740409dafd43eb7414b60
record_format Article
spelling doaj-1213022982c740409dafd43eb7414b602020-11-25T01:16:23ZengDove Medical PressResearch and Reports in Urology2253-24472013-03-012013default5365New therapeutic targets in the management of urothelial carcinoma of the bladderSverrisson EFEspiritu PNSpiess PEEinar F Sverrisson, Patrick N Espiritu, Philippe E SpiessDepartment of Genitourinary Oncology, H Lee Moffitt Cancer Center, Tampa, FL, USAAbstract: Urothelial carcinoma of the bladder, despite the myriad of treatment approaches and our progressively increasing knowledge into its disease processes, remains one of the most clinically challenging problems in modern urological clinical practice. New therapies target biomolecular pathways and cellular mediators responsible for regulating cell growth and metabolism, both of which are frequently overexpressed in malignant urothelial cells, with the intent of inducing cell death by limiting cellular metabolism and growth, creating an immune response, or selectively delivering or activating a cytotoxic agent. These new and novel therapies may offer a potential for reduced toxicity and an encouraging hope for better treatment outcomes, particularly for a disease often refractory or not amenable to the current therapeutic approaches.Keywords: targeted therapy, intravesical agents, systemic therapieshttp://www.dovepress.com/new-therapeutic-targets-in-the-management-of-urothelial-carcinoma-of-t-a12337
collection DOAJ
language English
format Article
sources DOAJ
author Sverrisson EF
Espiritu PN
Spiess PE
spellingShingle Sverrisson EF
Espiritu PN
Spiess PE
New therapeutic targets in the management of urothelial carcinoma of the bladder
Research and Reports in Urology
author_facet Sverrisson EF
Espiritu PN
Spiess PE
author_sort Sverrisson EF
title New therapeutic targets in the management of urothelial carcinoma of the bladder
title_short New therapeutic targets in the management of urothelial carcinoma of the bladder
title_full New therapeutic targets in the management of urothelial carcinoma of the bladder
title_fullStr New therapeutic targets in the management of urothelial carcinoma of the bladder
title_full_unstemmed New therapeutic targets in the management of urothelial carcinoma of the bladder
title_sort new therapeutic targets in the management of urothelial carcinoma of the bladder
publisher Dove Medical Press
series Research and Reports in Urology
issn 2253-2447
publishDate 2013-03-01
description Einar F Sverrisson, Patrick N Espiritu, Philippe E SpiessDepartment of Genitourinary Oncology, H Lee Moffitt Cancer Center, Tampa, FL, USAAbstract: Urothelial carcinoma of the bladder, despite the myriad of treatment approaches and our progressively increasing knowledge into its disease processes, remains one of the most clinically challenging problems in modern urological clinical practice. New therapies target biomolecular pathways and cellular mediators responsible for regulating cell growth and metabolism, both of which are frequently overexpressed in malignant urothelial cells, with the intent of inducing cell death by limiting cellular metabolism and growth, creating an immune response, or selectively delivering or activating a cytotoxic agent. These new and novel therapies may offer a potential for reduced toxicity and an encouraging hope for better treatment outcomes, particularly for a disease often refractory or not amenable to the current therapeutic approaches.Keywords: targeted therapy, intravesical agents, systemic therapies
url http://www.dovepress.com/new-therapeutic-targets-in-the-management-of-urothelial-carcinoma-of-t-a12337
work_keys_str_mv AT sverrissonef newtherapeutictargetsinthemanagementofurothelialcarcinomaofthebladder
AT espiritupn newtherapeutictargetsinthemanagementofurothelialcarcinomaofthebladder
AT spiesspe newtherapeutictargetsinthemanagementofurothelialcarcinomaofthebladder
_version_ 1725149971066388480